Scarica l'app Stockscreener
250.92
1.09%
2.71
Dopo l'orario di chiusura:
250.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$248.21
Aprire:
$247.04
Volume 24 ore:
696.88K
Relative Volume:
0.68
Capitalizzazione di mercato:
$36.63B
Reddito:
$5.26B
Utile/perdita netta:
$1.44B
Rapporto P/E:
25.68
EPS:
9.7713
Flusso di cassa netto:
$1.76B
1 W Prestazione:
+4.17%
1M Prestazione:
+0.35%
6M Prestazione:
-2.21%
1 anno Prestazione:
+6.25%
Intervallo 1D:
$246.85
$252.00
Intervallo di 1 settimana:
$240.00
$252.00
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
250.92 | 36.23B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
585.08 | 209.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.18 | 57.75B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.62 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
41.25 | 31.82B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Will ResMed Inc. stock gain from lower inflationJuly 2025 Catalysts & Expert Curated Trade Setups - ulpravda.ru
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Resmed Sets January 29 Date to Unveil Q2 FY2026 Results - TipRanks
ResMed CEO Michael Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - The Manila Times
Resmed Insider Sold Shares Worth $1,240,065, According to a Recent SEC Filing - MarketScreener
Will ResMed Inc. stock deliver stable dividendsJuly 2025 Action & Verified Short-Term Plans - ulpravda.ru
How ResMed Inc. (RME) stock performs during market turbulenceQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Is ResMed Inc. (RME) stock protected from inflationEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
An excellent week for ResMed Inc.'s (NYSE:RMD) institutional owners who own 69% as one-year returns inch higher - Yahoo Finance
Resmed Receives FDA Clearance for AI-Personalized CPAP Mask Settings - San Diego Business Journal
Is This the Right Time to Add Resmed Stock to Your Portfolio? - TradingView — Track All Markets
ResMed Director Peter Farrell Plans Additional Insider Share Sale Under Rule 144 - TipRanks
ResMed CFO Sells Small Block of Shares Under Pre-Arranged Trading Plan - TipRanks
Insider at company (NYSE: RMD) files Rule 144 to sell 2,000 shares - Stock Titan
RMD (RMD) insider Michael Farrell files to sell 4,991 common shares - Stock Titan
Will ResMed Inc. stock attract more institutional investorsVolume Analysis Techniques & Outperform With Our Smart Trading Calculator - ulpravda.ru
The Truth About ResMed Inc: Sleep Tech Darling or Overhyped Dinosaur? - AD HOC NEWS
ResMed stock in focus: sleep-tech leader tests investor conviction after choppy start to the year - AD HOC NEWS
EBIT per share of Resmed Inc. – OTC:RSMDF - TradingView — Track All Markets
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight - GlobeNewswire Inc.
ResMed updates CDI and share structure for December 2025 - MSN
Asset Management One Co. Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Updates CDI and Share Structure for December 2025 - TipRanks
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed (RMD) CFO discloses 1,000-share planned stock sale in Form 4 - Stock Titan
ResMed Executive Files Routine Rule 144 Notice for Small Share Sale - TipRanks
ResMed (NYSE:RMD) General Counsel Michael Rider Sells 50 Shares - MarketBeat
ResMed Inc (RMD) general counsel reports 50-share insider stock sale - Stock Titan
What you need to know ahead of ResMed's earnings release - MSN
ResMed Q2 2026 Earnings Preview: EPS Growth Forecast & Analyst Rating | BarchartNews and Statistics - IndexBox
ResMed Inc. $RMD Shares Sold by TriaGen Wealth Management LLC - MarketBeat
Railway Pension Investments Ltd Increases Position in ResMed Inc. $RMD - MarketBeat
What You Need to Know Ahead of ResMed's Earnings Release - Barchart.com
ResMed Inc. (RMD) Stock Analysis: Unveiling A 19.19% Potential Upside For Investors - DirectorsTalk Interviews
ResMed Inc.: How a Sleep-Tech Powerhouse Is Turning Data, Devices and Chronic Care Into a Platform P - AD HOC NEWS
Geopolitics Watch: Is ResMed Inc Common Stock RMEA stock overpriced at current multiplesWeekly Profit Summary & Weekly Return Optimization Plans - moha.gov.vn
ResMed Inc Reports Changes in CHESS Depositary Interests and Securities - MSN
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company - simplywall.st
RMD (ticker: RMD) insider Brett Sandercock files to sell 1,000 shares - Stock Titan
ResMed (RMD) insider plans Rule 144 sale of 50 common shares - Stock Titan
ResMed Inc. $RMD Shares Sold by Inspire Investing LLC - MarketBeat
Here's What ResMed's (NYSE:RMD) Strong Returns On Capital Mean - Yahoo Finance
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
The Truth About ResMed Inc: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
ResMed (RMD) Product Pipeline Analysis Report 2025 – ResearchAndMarkets.com - The AI Journal
ResMed (RMD) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Is ResMed CDI (ASX:RMD) Still Shaping Value For Investors? - Kalkine Media
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):